4
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      WHO-listed authorities (WLA) framework: transparent evidence-based approach for promoting regulatory reliance towards increased access to quality-assured medical products

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Increased global access to safe, effective and quality-assured medical products remains a primary goal for the full realization of the World Health Assembly Resolution WHA 67.20 on regulatory systems strengthening for medical products as well as target 3.8 of the Sustainable Development Goals (SDG). To promote the development of efficient regulatory systems, the WHO introduced the Global Benchmarking Tool (GBT) in 2016, upon which the WHO–Listed Authority (WLA) framework was later established. This study aimed to appraise the development of the WLA framework across various phases while highlighting its achievements, challenges, and areas for improvement.

          Methods

          An exploratory study design using a qualitative approach was used to gather information from relevant documents as well as views and experiences from purposefully selected participants from diverse backgrounds. Data was collected using a combination of desk reviews and In-depth one-to-one or small group interviews employing semi-structured interview guides with open-ended questions. Data was analysed using an inductive thematic analysis approach.

          Results

          The leading role of the WHO was noted in developing and implementing essential documents and mediating consultative processes among stakeholders. The framework was revealed to bring an evidence-based, inclusive, and transparent approach to recognizing regulatory authorities (RAs) operating at the highest standards of performance. The framework was anticipated to promote regulatory reliance among all RAs, the WHO’s prequalification programme, and procurement agencies. Furthermore, remarkable progress towards WLA listing was noted among transitional WLAs including the Stringent Regulatory Authorities (SRAs). Challenges related to the availability of resources, resistance to change, and complexity were associated with the framework.

          Conclusion

          The study provides a well-rounded view with regard to the roles of the WHO, Member States and other stakeholders in establishing and operationalizing the WLA framework. Furthermore, evaluating the performance and possible WLA designation of RAs operating at international regulatory standards underscores its high relevance in contributing to public health globally. Maintenance along with timely addressing of highlighted next steps to improve the framework particularly in creating better understanding, more communication, and coordination are highly encouraged.

          Related collections

          Most cited references27

          • Record: found
          • Abstract: not found
          • Article: not found

          Using thematic analysis in psychology

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Medicines Regulation in Africa: Current State and Opportunities

            Sound regulatory systems are critical for protecting public health against use of medical products which do not meet international standards of quality, safety and efficacy. This review provides a summary of the current status of National Medicines Regulatory Authorities (NMRAs) in Africa, and various initiatives that have been established to improve their performance. All countries in Africa (except Sahrawi Republic), have NMRAs but their organizational set-up and functionality is variable. Some are located within Ministries of Health and others are semi-autonomous. There is progressive improvement in regulatory capacity, particularly in quality control and post-marketing surveillance, pharmacovigilance and clinical trials oversight. The African Vaccines Regulatory Forum, African Medicines Regulatory Harmonization Initiative, Network of Official Medicines Control Laboratories and WHO Prequalification Scheme have helped countries strengthen their regulatory capacities. The potential establishment of the African Medicines Agency (AMA) in 2018 is an opportunity to improve NMRAs’ capacity in Africa.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Establishment of the African Medicines Agency: progress, challenges and regulatory readiness

              Insufficient access to quality, safe, efficacious and affordable medical products in Africa has posed a significant challenge to public health for decades. In part, this is attributed to weak or absent policies and regulatory systems, a lack of competent regulatory professionals in National Medicines Regulatory Authorities (NMRAs) and ineffective regional collaborations among NMRAs. In response to national regulatory challenges in Africa, a number of regional harmonisation efforts were introduced through the African Medicines Regulatory Harmonisation (AMRH) initiative to, among others, expedite market authorisation of medical products and to facilitate the alignment of national legislative frameworks with the AU Model Law on Medical Products Regulation. The goals of the model law include to increase collaboration across countries and to facilitate the overall regional harmonisation process. The AMRH initiative is proposed to serve as the foundation for the establishment of the African Medicines Agency (AMA). The AMA will, as one of its mandates, coordinate the regional harmonisation systems that are enabled by AU Model Law domestication and implementation. In this paper, we review the key entities involved in regional and continental harmonisation of medicines regulation, the milestones achieved in establishing the AMA as well as the implementation targets and anticipated challenges related to the AU Model Law domestication and the AMA’s establishment. This review shows that implementation targets for the AU Model Law have not been fully met, and the AMA treaty has not been ratified by the minimum required number of countries for its establishment. In spite of the challenges, the AU Model Law and the AMA hold promise to address gaps and inconsistencies in national regulatory legislation as well as to ensure effective medicines regulation by galvanising technical support, regulatory expertise and resources at a continental level. Furthermore, this review provides recommendations for future research.
                Bookmark

                Author and article information

                Contributors
                URI : http://loop.frontiersin.org/people/957044/overviewRole: Role: Role: Role: Role: Role: Role: Role: Role: Role: Role:
                URI : http://loop.frontiersin.org/people/2644675/overviewRole: Role: Role: Role: Role: Role: Role: Role:
                URI : http://loop.frontiersin.org/people/1027503/overviewRole: Role: Role: Role: Role: Role: Role:
                URI : http://loop.frontiersin.org/people/962070/overviewRole: Role: Role: Role: Role: Role: Role: Role: Role:
                URI : http://loop.frontiersin.org/people/957526/overviewRole: Role: Role: Role: Role:
                Role: Role: Role: Role:
                Journal
                Front Med (Lausanne)
                Front Med (Lausanne)
                Front. Med.
                Frontiers in Medicine
                Frontiers Media S.A.
                2296-858X
                23 September 2024
                2024
                : 11
                : 1467229
                Affiliations
                Regulation and Prequalification Department, World Health Organization , Geneva, Switzerland
                Author notes

                Edited by: Daniel O’Connor, Association of the British Pharmaceutical Industry (ABPI), United Kingdom

                Reviewed by: Giovanni Tafuri, Apellis Pharmaceuticals, United States

                Rolf Bass, Retired, Berlin, Germany

                *Correspondence: Alireza Khadem Broojerdi, khadembroojerdia@ 123456who.int
                Article
                10.3389/fmed.2024.1467229
                11456560
                39376648
                aff0eda6-d559-4526-9efe-6065865b3dc5
                Copyright © 2024 Broojerdi, Salvati, Abdelfattah, Dehaghi, Sillo and Gaspar.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 19 July 2024
                : 05 September 2024
                Page count
                Figures: 1, Tables: 3, Equations: 0, References: 27, Pages: 10, Words: 6725
                Funding
                The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was funded by the World Health Organization.
                Categories
                Medicine
                Original Research
                Custom metadata
                Regulatory Science

                who listed authority,wla,medicines regulation,stringent regulatory authorities,global benchmarking tool,reliance,regulatory systems strengthening,national regulatory authority

                Comments

                Comment on this article